CM Management’s Cymabay Therapeutics CBAY Stock Holding History

CM Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-160,000	Closed	-$1M	–	75
2022 Q4	$1M	Buy	160,000 +60,000	+60%	+$228K	1.2%	27
2022 Q3	$350K	Sell	100,000 -110,000	-52%	-$395K	0.39%	62
2022 Q2	$620K	Buy	210,000 +60,000	+40%	+$143K	0.66%	48
2022 Q1	$467K	Hold	150,000	–	–	0.39%	64
2021 Q4	$507K	Hold	150,000	–	–	0.38%	73
2021 Q3	$548K	Hold	150,000	–	–	0.41%	71
2021 Q2	$654K	Hold	150,000	–	–	0.47%	67
2021 Q1	$681K	Buy	+150,000	New	+$807K	0.51%	68

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CM Management's CBAY Position: Q1 2023 in Review

CM Management sold out of Cymabay Therapeutics (CBAY) in Q1 2023, closing a stake of 160,000 shares — an estimated $1M sold.

CM Management first reported a position in CBAY in Q1 2021 and held it in 8 quarters. The position peaked at $1M in Q4 2022. 139 funds tracked by Wall St. Rank hold CBAY as of Q1 2023.

CM Management reported no remaining Cymabay Therapeutics position as of Q1 2023 after selling out during the quarter.
CM Management sold 160,000 Cymabay Therapeutics shares in Q1 2023, an estimated $1M.
CM Management first reported a position in Cymabay Therapeutics in Q1 2021 and held it in 8 quarters.
CM Management's Cymabay Therapeutics position peaked at $1M in Q4 2022.
139 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2023.

Based on CM Management's 13F filing for Q1 2023, filed 8 May 2023.